Skip to content
Parakho

Wockhardt Ltd

NSE WOCKPHARMABSE 532300wockhardt.comInvestor relations

Q1 FY27, unaudited

Revenue
₹929.00 Cr
Profit after tax
₹107.00 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations929.00+25.88%3,373.00
Other income31.00+55.00%111.00
Total income960.00+26.65%3,484.00
Employee benefit expense203.00+18.71%725.00
Finance costs52.00+8.33%213.00
Depreciation & amortisation55.00−1.79%227.00
Total expenses844.00+9.61%3,161.00
Profit before tax116.00+206.42%238.00
Tax expense9.00+1,000.00%39.00
Profit after tax107.00+199.07%199.00
Total comprehensive income121.00+202.50%618.00
Earnings per share
Earnings per share, basic₹6.55₹13.12
Earnings per share, diluted₹6.55₹13.10

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Q4 FY26

Wockhardt reported FY26 revenue of INR3,373 crores with EBITDA of about INR630 crores, EBITDA growth of 51%, and profit before tax of INR238 crores, while EBITDA margin rose from 5.4% three years ago to 18.6%. Management described Zaynich, its novel antibiotic, receiving US FDA approval as a major milestone and laid out launch plans for the US, India, and emerging markets, alongside growth of 35% in the biosimilar business and 27% growth in the specialty segment. Executives also discussed capex plans, patent life, manufacturing strategy across India and Europe, and commercial partnership structures for the US launch.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 35 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 25 Aug 2026.